MK-8408
Total Payments
$249,185
Transactions
14
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $249,185 | 14 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $249,185 | 14 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open-Label, Single-Dose, Two-Period, Fixed-Sequence Study to Assess the Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance of MK-8408 in Healthy Adult Male Subjects | Merck Sharp & Dohme Corporation | $154,895 | 0 |
| A Two-Part, Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-3682 and MK-8408 when Coadministered to Subjects with Moderate and Severe Hepatic Insufficiency | Merck Sharp & Dohme Corporation | $94,290 | 0 |
Top Doctors Receiving Payments for MK-8408
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Orlando, FL | $249,185 | 14 |
Ad
Manufacturing Companies
- Merck Sharp & Dohme Corporation $249,185
Product Information
- Type Drug
- Total Payments $249,185
- Total Doctors 0
- Transactions 14
About MK-8408
MK-8408 is a drug associated with $249,185 in payments to 0 healthcare providers, recorded across 14 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2017. In 2017, $249,185 was paid across 14 transactions to 0 doctors.
The most common payment nature for MK-8408 is "Unspecified" ($249,185, 100.0% of total).
MK-8408 is associated with 2 research studies, including "An Open-Label, Single-Dose, Two-Period, Fixed-Sequence Study to Assess the Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance of MK-8408 in Healthy Adult Male Subjects" ($154,895).